Weight Loss Sale

Raynaud's Phenomenon

References

Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J. Rheumatol. 2008;35(9):1801-8.

Agostoni A, Marasini B, Biondi ML, et al. L-arginine therapy in Raynaud's phenomenon? Int. J. Clin. Lab Res. 1991;21(2):202-3.

Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci. 2004;75(6):639-53.

Ammer K. Diagnosis of Raynaud’s phenomenon by thermography. Skin Res Technol. 1996;2(4):182-5.

Baumhakel M, Bohm M. Recent achievements in the management of Raynaud's phenomenon. Vasc. Health Risk Manag. 2010;6:207-214.

Belch JJ, Shaw B, O'Dowd A, et al. Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study. Thromb. Haemost. 1985;54(2):490-4.

Bena J, et al. Evaluation of the Effect of Ambrisentan On Digital Microvascular Flow In Patients with Systemic Sclerosis Using Laser Doppler Perfusion Imaging. Paper presented at: American College of Rheumatology 2011; Chicago.

Bodelsson M, Arneklo-Nobin B, Nobin A, et al. Cooling enhances alpha 2-adrenoceptor-mediated vasoconstriction in human hand veins. Acta Physiol. Scand. 1990;138(3):283-91.

Boin F, Wigley FM. Understanding, assessing and treating Raynaud's phenomenon. Curr. Opin. Rheumatol. 2005;17(6):752-760.

Bredie SJ, Jong MC. No significant effect of ginkgo biloba special extract EGb 761 in the treatment of primary Raynaud phenomenon: a randomized controlled trial. J. Cardiovasc. Pharmacol. 2012;59(3):215-221.

Brigelius-Flohé R, Traber MG.Vitamin E: function and metabolism. FASEB J. 1999;13(10):1145-55.

Brueckner CS, Becker MO, Kroencke T, et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann. Rheum. Dis. 2010;69(8):1475-8.

Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo controlled study. Lancet. 2001;358(9288):1119-23.

Choi WS, Choi CJ, Kim KS, et al. To compare the efficacy and safety of nifedipine sustained release with Ginkgo biloba extract to treat patients with primary Raynaud's phenomenon in South Korea; Korean Raynaud study (KOARA study). Clin. Rheumatol. 2009 May;28(5):553-9.

Chung L, Shapiro L, Fiorentino D, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. Arthritis Rheum. 2009;60(3):870-7.

ClinicalTrials.gov. (a) Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon. NCT01280266. 2012; http://www.clinicaltrials.gov. Accessed December 26, 2012.

ClinicalTrials.gov. (b) PF-00489791 For The Treatment Of Raynaud's. NCT01090492 . 2012; http://www.clinicaltrials.gov. Accessed December 26, 2012.

Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 1994;270(1):228-35.

Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford). 2001;40(9):1038-43.

Cooke JP, Marshall JM. Mechanisms of Raynaud's disease. Vasc. Med. 2005;10(4):293-307.

Cutolo M, Pizzorni C, Secchi ME, Sulli A. Capillaroscopy. Best Pract. Res. Clin. Rheumatol. 2008;22(6):1093-108.

D'Angelo EK, Singer HA, Rembold CM.Magnesium relaxes arterial smooth muscle by decreasing intracellular Ca2+ without changing intracellular Mg2+. J. Clin. Invest. 1992;89(6):1988-94.

Delp HL, Newton RA. Effects of brief cold exposure on finger dexterity and sensibility in subjects with Raynaud's phenomenon. Phys. Ther. 1986;66(4):503-7.

Devulder J, van Suijlekom H, van Dongen R, Diwan S, Mekhail N, van Kleef M, Huygen F. Ischemic pain in the extremities and Raynaud's phenomenon. Pain Pract. 2011;11(5):483-91.

Dhar-Mascareno M, Carcamo JM, Golde DW. Hypoxia-reoxygenation-induced mitochondrial damage and apoptosis in human endothelial cells are inhibited by vitamin C. Free Radic. Biol. Med. 2005;38(10):1311-22.

DiGiacomo RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study. Am. J. Med. 1989;86(2):158-164.

Eid AH, Maiti K, Mitra S, et al. Estrogen increases smooth muscle expression of alpha2C-adrenoceptors and cold-induced constriction of cutaneous arteries. Am. J. Physiol. Heart Circ. Physiol. 2007;293(3):H1955-H61.

Fava A, Wung PK, Wigley FM, et al. Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon. Arthritis Care Res. (Hoboken). 2012;64(6):925-929.

Fraenkel L, Zhang Y, Chaisson CE, et al. The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women. Ann. Intern. Med. 1998 Aug 1;129(3):208-11.

Freedman RR, Baer Raynaud’s phenomenon, Mayes MD. Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud's disease. Circulation. 1995;92(6):1448-1451.

Gabbay E, Fraser J, McNeil K. Review of bosentan in the management of pulmonary arterial hypertension. Vasc. Health Risk Manag. 2007;3(6):887-900.

Gliddon AE, Dore CJ, Black CM, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum. 2007;56(11):3837-46.

Gokce N, Keaney JF, Jr., Frei B, et al. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 1999;99(25):3234-3240.

Goundry B, Bell L, Langtree M, Moorthy A. Diagnosis and management of Raynaud's phenomenon. BMJ. 2012;344:e289.

Harding SE, Tingey PC, Pope J, Fenlon D, Furst D, Shea B, Silman A, Thompson A, Wells GA. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database of Systematic Reviews 1998, Issue 2. Art. No.: CD000956.

Harrison’s Practice. Raynaud’s Phenomenon. Available at: http://www.harrisonspractice.com/practice/ub/view/Harrisons%20Practice/141268/all/raynaud%27s_phenomenon. Accessed January 10, 2013.

Harvard School of Public Health. The Nutrition Source: Omega-3 Fatty Acids. 2012; http://www.hsph.harvard.edu/nutritionsource/questions/omega-3. Accessed December 26, 2012.

Helou J, Moutran R, Maatouk I, Haddad F. Raynaud's phenomenon and vitamin D. Rheumatol. Int. 2012.

Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J. Rheumatol. 1994;21(8):1477-1483.

Herrick AL. Contemporary management of Raynaud's phenomenon and digital ischaemic complications. Curr. Opin. Rheumatol. 2011;23(6):555-61.

Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology. 2005;44(5):587-96.

Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nature reviews. Rheumatology. Aug 2012;8(8):469-479.

Holti G. An experimentally controlled evaluation of the effect of inositol nicotinate upon the digital blood flow in patients with Raynaud's phenomenon. J. Int. Med. Res. 1979;7(6):473-483.

Hummers LK, Dugowson CE, Dechow FJ, et al. A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon. Ann. Rheum. Dis. 2012. [Epub ahead of print]

Iorio ML, Masden DL, Higgins JP. Botulinum toxin A treatment of Raynaud's phenomenon: a review. Semin. Arthritis Rheum. 2012;41(4):599-603

Kamanna VS, Ganji SH, Kashyap ML. The mechanism and mitigation of niacin-induced flushing. Int. J. Clin. Pract. 2009 Sep;63(9):1369-77

Khan F, Belch JJ. Skin blood flow in patients with systemic sclerosis and Raynaud's phenomenon: effects of oral L-arginine supplementation. J. Rheumatol. 1999;26(11):2389-2394.

Khan F, Litchfield SJ, McLaren M, Veale DJ, Littleford RC, Belch JJ. Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon. Arthritis Rheum. 1997;40(2):352-357.

Khanna PP, Maranian P, Gregory J, Khanna D. The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial. Ann. Rheum. Dis. 2010;69:588-591.

Kirby BS, Voyles WF, Simpson CB, et al. Endothelium-dependent vasodilatation and exercise hyperaemia in ageing humans: impact of acute ascorbic acid administration. J. Physiol. 2009;587(Pt 9):1989-2003.

Kleinert H, Wallerath T, Euchenhofer C, Ihrig-Biedert I, Li H, Forstermann U. Estrogens Increase Transcription of the Human Endothelial NO Synthase Gene : Analysis of the Transcription Factors Involved. Hypertension. 1998;31(2):582-8.

Kuhar CG, Mesti T, Zakotnik B. Digital ischemic events related to gemcitabine: Report of two cases and a systematic review. Radiol. Oncol. 2010;44(4):257-61.

Kuwana M, Kaburaki J, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum. 2006;54(6):1946-1951.

Lambova SN, Muller-Ladner U. New lines in therapy of Raynaud's phenomenon. Rheumatol. Int. 2009;29(4):355-363.

Leppert J, Aberg H, Levin K, Ringqvist I, Jonason T. The concentration of magnesium in erythrocytes in female patients with primary Raynaud's phenomenon; fluctuation with the time of year. Angiology. 1994a;45(4):283-288.

Leppert J, Aberg H, Levin K, Ringqvist I. Lower serum magnesium level after exposure to cold in women with primary Raynaud's phenomenon. J. Intern. Med. 1990;228(3):235-9.

Leppert J, Myrdal U, Hedner T, Edvinsson L, Tracz Z, Ringqvist I. Effect of magnesium sulfate infusion on circulating levels of noradrenaline and neuropeptide-Y-like immunoreactivity in patients with primary Raynaud's phenomenon. Angiology. 1994b;45(7):637-645.

Leppert J, Myrdal U, Hedner T, Edvinsson L, Tracz Z, Ringqvist I. Magnesium sulphate increases plasma noradrenaline and neuropeptide-Y-like immunoreactivity. Lancet. 1995;346(8985):1307-1308.

Levien TL. Advances in the treatment of Raynaud's phenomenon. Vasc. Health Risk Manag. 2010;6:167-177.

Malenfant D, Summers K, Seney S, et al. Results of a Pilot Randomized Placebo-Controlled Trial in Primary and Secondary Raynaud's Phenomenon with St. John's Wort: Detecting Changes in Angiogenic Cytokines When Raynaud’s phenomenon Improves. ISRN Rheumatol. 2011;2011:580704.

Martínez JD. Raynaud phenomenon - First Consult. 2011; https://www.clinicalkey.com/#!/ContentPlayerCtrl/doPlayContent/21-s2.0-1014243/{"scope":"all","query":"raynaud"}. Accessed 3/26/2013.

Matoba T, Kusumoto H, Mizuki Y, et al. Comparative double-blind trial of dl-alpha-tocopheryl nicotinate on vibration disease. Tohoku J. Exp. Med. 1977;123(1):67-75.

Matucci Cerinic M, Kahaleh MB. Beauty and the beast. The nitric oxide paradox in systemic sclerosis. Rheumatology. 2002;41(8):843-7.

Mayo Clinic. Alpha blockers. 2010a; http://www.mayoclinic.com/health/alpha-blockers/HI00055. Accessed December 21, 2012.

Mayo Clinic. Angiotensin II receptor blockers. 2011a; http://www.mayoclinic.com/health/angiotensin-II-receptor-blockers/HI00054. Accessed January 31, 2031

Mayo Clinic. Angiotensin-converting enzyme (ACE) inhibitors. 2010b; http://www.mayoclinic.com/health/ace-inhibitors/HI00060. Accessed December 21, 2012.

Mayo Clinic. Atorvastatin (Oral Route). 2012e; http://www.mayoclinic.com/health/drug-information/DR601517. Accessed December 21, 2012.

Mayo Clinic. Calcium channel blockers. 2010c http://www.mayoclinic.com/health/calcium-channel-blockers/HI00061. Accessed January 31, 2013.

Mayo Clinic. Cilostazol (Oral Route). 2012a; http://www.mayoclinic.com/health/drug-information/DR601833. Accessed January 31, 2013.

Mayo Clinic. Pentoxifylline (Oral Route). 2011b; http://www.mayoclinic.com/health/drug-information/DR601099. Accessed December 21, 2012.

Mayo Clinic. Raynaud's Disease: Treatments and Drugs. 2011c; http://www.mayoclinic.com/health/raynauds-disease/. Accessed December 21, 2012.

Mayo Clinic. Selective serotonin reuptake inhibitors (SSRIs). 2010d; http://www.mayoclinic.com/health/ssris/MH00066. Accessed December 21, 2012.

Mayo Clinic. Sildenafil (Oral Route). 2012b. http://www.mayoclinic.com/health/drug-information/DR601513 Accessed on January 31, 2013.

Mayo Clinic. Tadalafil (Oral Route). 2012c. http://www.mayoclinic.com/health/drug-information/DR601567 Accessed on January 31, 2013.

Mayo Clinic. Vardenafil (Oral Route). 2012d. http://www.mayoclinic.com/health/drug-information/DR601541 Accessed January 31, 2013

MediQuest Therapeutics 2008. MQX-503 Findings to be Presented at International Scleroderma Conference. Available at: http://www.mqti.com/news.cfm?aId=9B8FFCEB-C298-58F6-03BD21CD0FC3EC71. Last reviewed January 31, 2013

MediQuest Therapeutics 2012. Phase 3 Topical Drug for Raynaud's Disease Available for Licensing/Acquisition at the J.P. Morgan Conference [press release]. December 13, 2012; http://finance.yahoo.com/news/phase-3-topical-drug-raynauds-182200776.html. Accessed December 20, 2012.

MedlinePlus. Bosentan. 2010. Available at: http://www.nlm.nih.gov/medlineplus/druginfo/meds/a605001.html. Accessed December 21, 2012.

Milton SG, Robinson K, Ma J, Wei B, Poon IO, Liang D. Biotransformation and pharmacokinetics of inositol hexanicotinate in rats. Xenobiotica; the fate of foreign compounds in biological systems. Jan 24 2013.

Muir AH, Robb R, McLaren M, Daly F, Belch JJF. The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial. Vasc. Med. 2002;7(4):265-7.

Myrdal U, Leppert J, Edvinsson L, et al. Magnesium sulphate infusion decreases circulating calcitonin gene-related peptide (CGRP) in women with primary Raynaud's phenomenon. Clin Physiol. 1994;14(5):539-46.

NCBI 2011. Raynaud's Phenomenon. Available at: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001449/. Last reviewed June 2011.

Nguyen VA, Eisendle K, Gruber I, Hugl B, Reider D, Reider N. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatology. Mar 2010;49(3):583-587.

NIAMS. What is Raynaud’s Phenomenon? Available at: http://www.niams.nih.gov/health_info/raynauds_phenomenon/raynauds_phenomenon_ff.pdf. 2009. Last accessed January 30 2013.

Nusgens BV, Humbert P, Rougier A, et al. Topically applied vitamin C enhances the mRNA level of collagens I and III, their processing enzymes and tissue inhibitor of matrix metalloproteinase 1 in the human dermis. J. Invest. Dermatol. 2001;116(6):853-9.

Paick JS, Kim SW, Yang DY, et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J. Sex. Med. 2008;5(4):946-53

Pauling JD, Shipley JA, Harris ND, McHugh NJ. Use of infrared thermography as an endpoint in therapeutic trials of Raynaud's phenomenon and systemic sclerosis. Clin. Exp. Rheumatol. 2012;30(2 Suppl 71):S103-S15.

Pavlov-Dolijanovic S, Damjanov NS, Vujasinovic Stupar NZ, et al. Late appearance and exacerbation of primary Raynaud's phenomenon attacks can predict future development of connective tissue disease: a retrospective chart review of 3,035 patients. Rheumatol. Int. 2012 Jul 22.

Planchon B, Pistorius MA, Beurrier P, De Faucal P. Primary Raynaud's phenomenon. Age of onset and pathogenesis in a prospective study of 424 patients. Angiology. 1994 Aug;45(8):677-86.

Rembold CM, Ayers CR. Oral L-arginine can reverse digital necrosis in Raynaud's phenomenon. Mol. Cell. Biochem. 2003;244(1-2):139-141.

Rosato E, Borghese F, Pisarri S, Salsano F. The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients. Clin. Rheumatol. 2009;28(12):1379-84.

Rosato E, Molinaro I, Borghese F, Rossi C, Pisarri S, Salsano F. Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension. The Journal of rheumatology. Dec 2010;37(12):2531-2539.

Rosenson R. Antiatherothrombotic effects of nicotinic acid. Atherosclerosis. 2003;171(1):87-96.

Roustit M, Blaise S, Millet C, Cracowski JL. Impaired transient vasodilation and increased vasoconstriction to digital local cooling in primary Raynaud's phenomenon. Am. J. Physiol. Heart Circ. Physiol. 2011;301(2):H324-H30.

Salsano F, Letizia C, Proietti M, et al. Significant changes of peripheral perfusion and plasma adrenomedullin levels in N-acetylcysteine long term treatment of patients with sclerodermic Raynaud’s phenomenon. Int. J. Immunopathol. Pharmacol. 2005;18(4):761-770.

Sambo P, Amico D, Giacomelli R, et al. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. J. Rheumatol. 2001;28(10):2257-2262.

Seelig MS. Consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications (a review). J. Am Coll. Nutr. 1994;13(5):429-46.

Selbold JR, et al. Digital ischemic ulcers in scleroderma treated with oral treprostinil diethanolamine: a randomized, double-blind, placebo-controlled, multicenter study. Paper presented at: American College of Rheumatology; 2011; Chicago.

Selenko-Gebauer N, Duschek N, Minimair G, Stingl G, Karlhofer F. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan. Rheumatology. Oct 2006;45 Suppl 3:iii45-48.

Simonini G, Pignone A, Generini S, et al. Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology. 2000;155(1-3):1-15.

Simonini G, Pignone A, Generini S, Falcini F, Cerinic MM. Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology. Nov 30 2000;155(1-3):1-15.

Stewart M, Morling JR. Oral vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst. Rev. 2012;7:CD006687.

Stücker O, Pons C, Duverger JP, et al. Effect of Ginkgo biloba extract (EGb 761) on the vasospastic response of mouse cutaneous arterioles to platelet activation. Int. J. Microcirc. Clin. Exp. 1997;17(2):61-6.

Sunderland GT, Belch JJ, Sturrock RD, et al. A double-blind randomised placebo controlled trial of hexopal in primary Raynaud’s disease. Clin. Rheumatol. 1988;7:46-49.

Sung HH, Lee SW. Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction. Korean J. Urol. 2012;53(6):377-85.

Suter LG, Murabito JM, Felson DT, Fraenkel L. Smoking, alcohol consumption, and Raynaud's phenomenon in middle age. Am. J. Med. 2007;120(3):264-71.

Thomas P, Pang Y. Protective actions of progesterone in the cardiovascular system: Potential role of membrane progesterone receptors (mPRs) in mediating rapid effects. Steroids. Jan 25 2013.

Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxford). 2005;44(2):145-50.

Thompson RW. Challenges in the treatment of thoracic outlet syndrome. Tex. Heart Inst. J. 2012;39(6):842-3.

Tikly M, Channa K, Theodorou P, Gulumian M. Lipid peroxidation and trace elements in systemic sclerosis. Clin. Rheumatol. 2006;25(3):320-4.

Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ.Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann. Intern. Med. 1981;95(3):288-92.